GHP Investment Advisors Inc. Purchases 419 Shares of DaVita Inc. (NYSE:DVA)

GHP Investment Advisors Inc. boosted its position in shares of DaVita Inc. (NYSE:DVA) by 0.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,725 shares of the company’s stock after buying an additional 419 shares during the quarter. GHP Investment Advisors Inc. owned 0.05% of DaVita worth $7,496,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Fox Hill Wealth Management increased its holdings in DaVita by 138.4% during the first quarter. Fox Hill Wealth Management now owns 15,734 shares of the company’s stock valued at $2,172,000 after buying an additional 9,135 shares during the period. Dumont & Blake Investment Advisors LLC raised its stake in shares of DaVita by 2.1% during the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 8,290 shares of the company’s stock valued at $1,144,000 after buying an additional 170 shares during the last quarter. Panoramic Investment Advisors LLC purchased a new position in shares of DaVita during the 1st quarter valued at approximately $203,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of DaVita by 1.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company’s stock valued at $18,612,000 after acquiring an additional 2,129 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in DaVita during the first quarter valued at $220,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Price Performance

Shares of NYSE:DVA traded down $4.39 on Friday, hitting $156.99. The company had a trading volume of 854,416 shares, compared to its average volume of 802,997. The business has a 50 day moving average of $158.09 and a 200 day moving average of $145.50. DaVita Inc. has a 52-week low of $75.47 and a 52-week high of $168.50. The company has a market cap of $13.77 billion, a PE ratio of 17.84, a PEG ratio of 0.93 and a beta of 0.87. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. During the same period in the previous year, the company earned $2.08 EPS. DaVita’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock valued at $27,387,069 in the last 90 days. 2.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DVA. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen upped their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Finally, Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $159.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.